• About us
• Contact

Advertisement

Organisation › Details

American Society of Clinical Oncology (ASCO)

	Start	1999-04-24 existent
	Industry	oncology
	City	n. a.
		Address record changed: 2011-05-15
Basic data	Employees	n. a.
		Record changed: 2020-02-12

Advertisement

More documents for American Society of Clinical Oncology (ASCO)

• [1] Roche. (5/14/20). "Press Release: Roche to Present First Clinical Data on Novel Anti-TIGIT Cancer Immunotherapy Tiragolumab at ASCO". Basel....
• [2] Proteomedix AG. (2/11/20). "Press Release: New Data from Proclarix together with Magnetic Resonance Imaging (MRI) for Improved Prostate Cancer Diagnosis to Be Showcased at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium". Zür...
• [3] Sanofi S.A.. (6/2/19). "Press Release: Phase 3 Trial of Isatuximab Combination Therapy Showed 40% Reduction in the Risk of Disease Progression or Death for Patients with Relapsed/Refractory Multiple Myeloma". Paris....
• [4] Polyphor Ltd.. (5/17/19). "Press Release: Polyphor Announces Presentation of New Survival Data on Balixafortide at the ASCO Annual Meeting 2019". Allschwil....
• [5] Roche. (5/16/19). "Press Release: Roche’s Personalised Medicine Entrectinib Shrank Tumours Harbouring NTRK, ROS1 or ALK Gene Fusions in Children and Adolescents". Basel....
• [6] Medigene AG. (5/8/19). "Press Release: Medigene Participates at Upcoming Conferences". Martinsried....
• [7] Bavarian Nordic A/S. (5/16/18). "Press Release: Bavarian Nordic Announces Acceptance of Abstracts and Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting". Copenhagen....
• [8] Roche. (6/5/17). "Press Release: Phase III Study Showed Roche’s Alecensa (alectinib) Reduced the Risk of Disease Progression or Death by more than Half versus Crizotinib as First-line Treatment in a Specific Type of Lung Cancer". Basel....
• [9] Boehringer Ingelheim. (6/5/17). "Press Release: Encouraging Phase II Survival Data for Nintedanib in Malignant Pleural Mesothelioma Presented at ASCO 2017". Ingelheim....
• [10] Roche. (6/3/17). "Press Release: Roche Presents New Data for Tecentriq (atezolizumab) and Updates from Across Its Cancer Immunotherapy Development Programme at ASCO 2017". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.